Avalyn to Participate in the Jefferies Global Healthcare Conference
Rhea-AI Summary
Avalyn (Nasdaq: AVLN) will present a company overview at the Jefferies Global Healthcare Conference in New York on June 4, 2026, from 9:55–10:25 a.m. ET. A live webcast and archived recording will be available on Avalyn’s investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction – AVLN
In the May 27 session, AVLN gained 0.45%, reflecting a mild positive market reaction. Argus tracked a peak move of +4.9% during that session. Our momentum scanner triggered 19 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 21 | Conference data preview | Positive | +1.4% | Announced upcoming EULAR 2026 long-term AP01 pulmonary fibrosis data. |
| May 05 | Scientific posters update | Positive | +1.0% | Detailed AP01 usability and supportive-care posters at ATS 2026. |
| May 03 | Sector M&A highlight | Positive | -2.6% | Highlighted UCB’s Candid deal and Avalyn’s inclusion among Vida IPOs. |
| May 01 | IPO closing | Positive | -2.6% | Closed IPO and underwriters’ option, listing AVLN on Nasdaq. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent scientific/clinical conference communications saw modest positive reactions, while corporate/IPO-related headlines coincided with short-term weakness.
Over the past month, Avalyn has focused updates on scientific visibility and its market debut. On May 21, 2026, it highlighted upcoming long-term AP01 data at EULAR 2026, with a modest positive move. Earlier, on May 5, 2026, it announced patient-centered AP01 research posters for ATS 2026, again with a small gain. In contrast, news tied to capital markets and broader ecosystem—an Avalyn-referenced M&A highlight on May 3 and the IPO closing on May 1—saw mild negative reactions. Today’s Jefferies conference appearance fits the theme of ongoing investor and scientific outreach.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced Avalyn management will present a company overview at the Jefferies Global Healthcare Conference in New York City on June 4, 2026, at 9:55-10:25 a.m. ET.
Access to the live webcast of this event, and the archived recording, will be posted under the News & Events page of the Investor section of the company’s website at https://investors.avalynpharma.com/
About Avalyn Pharma
Avalyn aims to transform the treatment paradigm for pulmonary fibrosis and other serious, rare respiratory diseases. The company is advancing optimized inhaled formulations of established antifibrotic medicines designed to deliver drug directly to the lungs, enhance local efficacy, and reduce systemic side effects. Avalyn’s AP01 program is an optimized inhaled formulation of pirfenidone currently being evaluated in MIST, a global Phase 2b clinical trial in patients with progressive pulmonary fibrosis (PPF). AP01 has indicated encouraging safety and clinical activity across Phase 1b and ongoing, multi-year open-label extension trials, with long-term data supporting the potential to preserve lung function while improving tolerability relative to historical oral pirfenidone. Avalyn’s AP02 program is an optimized inhaled formulation of nintedanib currently being evaluated in AURA-IPF, a global Phase 2 clinical trial in patients with idiopathic pulmonary fibrosis (IPF). Avalyn is also advancing AP03, an inhaled fixed-dose combination of pirfenidone and nintedanib, designed to deliver multiple antifibrotic mechanisms through a single lung-targeted platform. By leveraging its proprietary drug-device approach and deep expertise in rare respiratory disease development, Avalyn aims to establish a new standard of care in pulmonary fibrosis through inhaled, lung-targeted therapies. For more information, please visit avalynpharma.com and follow the company on LinkedIn.
Investor Contact:
Cassie Saitow, Avalyn Pharma Inc.
Sr. Director, IR and Corporate Communications
ir@avalynpharma.com
Media Contact:
Kat Lippincott, Deerfield Group
kat.lippincott@deerfieldgroup.com
media@avalynpharma.com
